Slide 9 | NERV Message Board Posts

Minerva Neurosciences Inc.

  NERV website

NERV   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  654 of 683  at  5/29/2020 12:48:32 PM  by

biobetter

The following message was updated on 5/29/2020 4:49:53 PM.

 In response to msg 653 by  BelieverTim
view thread

Re: Slide 9

This P3 took too long and another P3 will allow competitors like Karuna & Sunovion to catch up in schizo neg sym. The positive for 101 is the new formulation provides a longer patent life out to around 2035 so there is time for another try. The huge negative for NERV is it has very little money left to run another P3. 202's P2 data was weak for MDD but good for insomnia. There are already 2 approved orexins for insomnia and another one is on the way after recent good P3 data. But being 4th out of the gate for the insomnia market reduces that indication's value a lot imo. 202's had good MDD with insomnia data & that impressed JNJ enough to plan a P3. If they start a couple of P3s this year 202 could have the lead there. Tim I wish you & the rest luck but I was here strictly for schizo so I've sold the rest of my NERV.  


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 4     Views: 106
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
656 Re: Slide 9 Paul777333 3 5/29/2020 2:09:50 PM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...